A new tool being used at Houston Methodist taps into artificial intelligence breast cancer diagnosis. Photo courtesy of Houston Methodist

In the medical field, billions of dollars are wasted each year — about $935 billion, but who's counting? According to a paper published by the JAMA Network, an estimated $75.7 billion to $101.2 billion is wasted through overtreatment. Of the many procedures that can lead to wasted resources, breast cancer biopsies are a major source of overtreatment. Houston Methodist Hospital is using artificial intelligence to create a more efficient and accurate Breast Cancer Risk Calculator, called iBrisk.

Breast cancer is something that plagues the lives of many women, and some men. According to the National Breast Cancer Foundation, one in eight women will be diagnosed with breast cancer in their lifetime.

Women are advised to start having annual mammograms to screen for breast cancer starting at age 40 to try to catch cancer in its earliest stages. With mammograms becoming a standard procedure, the process inevitably leads to more biopsies.

While more biopsies sound like the obvious course of action, Houston Methodist Hospital shares that out of 10,000 women biopsied, less than two will be positive while using the national standard. The result of a negative biopsy? Wasted time, resources, and money, as well as undue worry for the patient.

"It's not just wasteful. . .when you do an unnecessary procedure, you're potentially harming the patient," says Stephen Wong, Ph.D. After a negative biopsy, Dr. Wong explains that patients often begin to show emotional responses like high anxiety and low self-esteem. They often speculate the biopsies are wrong, and that they've had a missed cancer diagnosis by their medical provider.

Dr. Wong estimates that more than 700,000 patients have unnecessary biopsies in the breast cancer category alone.

Spearheading the iBrisk tool, Dr. Wong has found a way to utilize a smarter model than the current system for detecting breast cancer risk.

Hospitals across the country currently use the Breast Imaging Reporting and Database System score (BI-RADS), a system created by the American College of Radiology to determine breast cancer risk and biopsy decision-making.

To expand on BI-RADS data, Dr. Wong used multiple patient data points and AI technology to create the improved system. The iBRISK integrates natural language processing, medical image analysis, and deep learning on multi-modal BI-RADS patient data to make one of three recommendations: biopsy not recommended, consider biopsy, or biopsy recommended.

"While using AI, we try to simulate how the physician thinks," explains Dr. Wong. "The physician looks at different data: imaging, patient clinical data, demographic, history and other social factors. You don't rely on one particular thing."

To create iBrisk, Dr. Wong used 12 to 13 years of BI-RAD data at Houston Methodist Hospital to train the AI using deep learning.

He estimates that more than 80 percent of technical information is in the free text format, meaning unstructured data, in the United States.

"We applied an AI technique called natural language processing, which is using the computer to read the text automatically for us," explains Dr. Wong.

This data extraction tool was also used with imaging of mammogram ultrasounds by applying image analysis computer vision.

iBrisk also deploys deep learning, a machine learning tactic where artificial neural networks, inspired by the human brain, learn from large amounts of data. They determined approximately 100 parameters to analyze, including age, sex, socio-economic data, medical history, and insurance plans. After putting the data points into a deep learning method, the AI reduced the data points to the 20 risk indicators.

Houston Methodist Hospital used an estimated 11,000 cases for training, and then used 2,200 of its own data to test iBrisk. They have even been able to create unbiased independent validation by working with other hospitals like MD Anderson, testing their patients using iBrisk and confirming the results.

The potential of iBrisk to cut costs and contribute to less overtreatment has garnered support with other hospitals around the country. The breast cancer risk calculator is a collaboration with Dr. Jenny Chang of HMCC and breast oncologists at MD Anderson, UT San Antonio, and University of Utah Cancer Center.

While implicit racial bias has become a more prominent issue in the United States, Houston Methodist's iBrisk grants a neutral, unbiased lens. AI isn't immune to racial bias; in fact, computer scientist and founder of the Algorithmic Justice League, Joy Buolamwini, uncovered the large gender and racial biases of AI systems sold by IBM, Amazon and Microsoft in a 2019 article for Time.

With AI's history of racial bias in mind, Dr. Wong set out to create an impartial, fair system. "Our AI data is not sensitive to race. . .it's unbiased," he explains.

Houston Methodist Hospital plans to expand the iBrisk model to other forms of cancer in the future, including its next venture into thyroid and incidental lung nodule screenings.

The AI allows patients to save the stress of getting a biopsy.

"We are very careful to put any drugs or any procedure into clinical workflow until we are very sure you really have to pick this [outcome]," explains Dr. Wong. Using advanced risk detectors like iBrisk allows medical practitioners to make more thorough, informed decisions for patients looking into biopsies.

The categories are broken into low, moderate and high-risk groups. The low-risk groups have seen a 99.8 percent accuracy in results, missing only two cases out of a sample of 1,228. Patients that have fallen into the high-risk groups (leading patients to get a biopsy) have seen an 85.9 percent accuracy, compared to radiology, which is 25 percent accurate according to Dr. Wong.

Dr. Wong notes that patients that fall in the moderate section of the risk assessment can then have a dialogue with their physician to determine if they want to move forward with the biopsy. In the moderate category, there is a 93.4 percent accuracy.

If implemented, iBrisk would be able to reduce 75 percent of unnecessary biopsies, estimates Dr. Wong.

Currently, Houston Methodist Hospital is using AI technology outside of oncology, with the recent release of a tool that can diagnose strokes using a smartphone, announced in Science Daily. The tool, which can diagnose abnormalities in a patient's speech and facial muscular movements, was made in collaboration with Dr. Jay Volpi of Eddy Scullock Stroke Center at Houston Methodist Hospital.

"We are answering bigger questions," explains Dr. Wong, who looks forward to continuing to expand AI capabilities and risk calculators at Houston Methodist Hospital.

In the future, Dr. Wong looks forward to doing a multicenter trial to bring this technology outside of Texas.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup taps strategic partner to produce novel 'biobased leather'

cleaner products

A Houston-based next-gen material startup has revealed a new strategic partnership.

Rheom Materials, formerly known as Bucha Bio, has announced a strategic partnership with thermoplastic extrusion and lamination company Bixby International, which is part of Rheom Material’s goal for commercial-scale production of its novel biobased material, Shorai.

Shorai is a biobased leather alternative that meets criteria for many companies wanting to incorporate sustainable materials. Shorai performs like traditional leather, but offers scalable production at a competitive price point. Extruded as a continuous sheet and having more than 92 percent biobased content, Shorai achieves an 80 percent reduction in carbon footprint compared to synthetic leather, according to Rheom.

Rheom, which is backed by Houston-based New Climate Ventures, will be allowing Bixby International to take a minority ownership stake in Rheom Materials as part of the deal.

“Partnering with Bixby International enables us to harness their extensive expertise in the extrusion industry and its entire supply chain, facilitating the successful scale-up of Shorai production,” Carolina Amin Ferril, CTO at Rheom Materials, says in a news release. “Their highly competitive and adaptable capabilities will allow us to offer more solutions and exceed our customers’ expectations.”

In late 2024, Rheom Materials started its first pilot-scale trial at the Bixby International facilities with the goal of producing Shorai for prototype samples.

"The scope of what we were doing — both on what raw materials we were using and what we were creating just kept expanding and growing," founder Zimri Hinshaw previously told InnovationMap.

Listen to Hinshaw on the Houston Innovators Podcast episode recorded in October.

Justice Department sues to block Houston-based HPE's $14B buyout of Juniper

M&A News

The Justice Department sued to block Hewlett Packard Enterprise's $14 billion acquisition of rival Juniper Networks on Thursday, the first attempt to stop a merger by a new Trump administration that is expected to take a softer approach to mergers.

The Justice complaint alleges that Hewlett Packer Enterprise, under increased competitive pressure from the fast-rising Juniper, was forced to discount products and services and invest more in its own innovation, eventually leading the company to simply buy its rival.

The lawsuit said that the combination of businesses would eliminate competition, raise prices and reduce innovation.

HPE and Juniper issued a joint statement Thursday, saying the companies strongly oppose the DOJ's decision.

“We will vigorously defend against the Department of Justice’s overreaching interpretation of antitrust laws and will demonstrate how this transaction will provide customers with greater innovation and choice, positively change the dynamics in the networking market,” the companies said.

The combined company would create more competition, not less, the companies said.

The Justice Department's intervention — the first of the new administration and just 10 days after Donald Trump's inauguration — comes as somewhat of a surprise. Most predicted a second Trump administration to ease up on antitrust enforcement and be more receptive to mergers and deal-making after years of hypervigilance under former President Joe Biden’s watch.

Hewlett Packard Enterprise announced one year ago that it was buying Juniper Networks for $40 a share in a deal expected to double HPE’s networking business.

In its complaint, the government painted a picture of Hewlett Packard Enterprise as a company desperate to keep up with a smaller rival that was taking its business.

HPE salespeople were concerned about the “Juniper threat,” the complaint said, also alleging that one former executive told his team that “there are no rules in a street fight,” encouraging them to “kill” Juniper when competing for sales opportunities.

The Justice Department said that Hewlett Packard Enterprise and Juniper are the U.S.'s second- and third-largest providers of wireless local area network (WLAN) products and services for businesses.

“The proposed transaction between HPE and Juniper, if allowed to proceed, would further consolidate an already highly concentrated market — and leave U.S. enterprises facing two companies commanding over 70% of the market,” the complaint said, adding that Cisco Systems was the industry leader.

Many businesses and investors accused Biden regulatory agencies of antitrust overreach and were looking forward to a friendlier Trump administration.

Under Biden, the Federal Trade Commission sued to block a $24.6 billion merger between Kroger and Albertsons that would have been the largest grocery store merger in U.S. history. Two judges agreed with the FTC’s case, blocking the proposed deal in December.

In 2023, the Department of Justice, through the courts, forced American and JetBlue airlines to abandon their partnership in the northeast U.S., saying it would reduce competition and eventually cost consumers hundreds of millions of dollars a year. That partnership had the blessing of the Trump administration when it took effect in early 2021.

U.S. regulators also proposed last year to break up Google for maintaining an “abusive monopoly” through its market-dominate search engine, Chrome. Court hearings on Google’s punishment are scheduled to begin in April, with the judge aiming to issue a final decision before Labor Day. It’s unclear where the Trump administration stands on the case.

One merger that both Trump and Biden agreed shouldn’t go through is Nippon Steel’s proposed acquisition of U.S. Steel. Biden blocked the nearly $15 billion acquisition just before his term ended. The companies challenged that decision in a federal lawsuit early this year.

Trump has consistently voiced opposition to the deal, questioning why U.S. Steel would sell itself to a foreign company given the regime of new tariffs he has vowed.